SCHEMBL18548857

SCHEMBL18548857

COC(=O)c1c(C)n(-c2ccccc2)c2ccc(C)cc2c1=O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.67
KDM4E B2RXH2 5/20 0.67
HPGD P15428 5/20 0.67
PKM P14618 2/20 0.67
ALOX15 P16050 2/20 0.67
HSD17B10 Q99714 2/20 0.67
CYP1A2 P05177 1/20 0.67
CYP3A4 P08684 1/20 0.67
CYP2D6 P10635 1/20 0.67
CYP2C9 P11712 1/20 0.67
CYP2C19 P33261 1/20 0.67
GAA P10253 3/20 0.60
GFER P55789 1/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
HTT P42858 5/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
LMNA P02545 1/20 0.53
MAPK1 P28482 2/20 0.52
TSHR P16473 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18548860 0.87 GAA (0.63) MAPTKDM4EHPGDPKMALOX15
SCHEMBL18548838 0.83 KDM4E (0.50) MAPTKDM4EHPGDPKMALOX15
SCHEMBL11791554 0.81 HPGD (0.59) MAPTKDM4EHPGDPKMALOX15
SCHEMBL16344509 0.80 MAPT (0.75) MAPTKDM4EHPGDPKMALOX15
SCHEMBL1611328 0.78 KDM4E (0.48) MAPTKDM4EHPGDPKMALOX15
SCHEMBL10461275 0.76 KDM4E (0.52) MAPTKDM4EHPGDPKMALOX15
SCHEMBL13833031 0.74 KDM4E (0.53) MAPTKDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL8335042 0.73 MAPT (0.58) MAPTKDM4EHPGDPKMALOX15
SCHEMBL18969702 0.72 GAA (0.48) MAPTKDM4EHPGDPKMALOX15
SCHEMBL5088290 0.71 MAPT (0.55) MAPTKDM4EHPGDPKMALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108473434-B Substituted quinolone derivative or pharmaceutically acceptable salt or stereoisomer thereof, and medicinal composition and application thereof 上海海和药物研究开发股份有限公司 2021-11-23 CN disclosed
EP-3339294-B1 QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER THEREOF AS AXL INHIBIOTOR SHANGHAI HAIHE PHARMACEUTICAL CO LTD (CN) 2021-04-14 EP disclosed
US-10683278-B2 Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) 2020-06-16 US disclosed
US-10683278-B2 Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) 2020-06-16 US disclosed
CN-106467541-B Substituted quinolone analog derivative or its pharmaceutically acceptable salt or stereoisomer and its Pharmaceutical composition and application 暨南大学 2019-04-05 CN disclosed
US-20180265496-A1 SUBSTITUTED QUINOLONE DERIVATIVES, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR STEREOISOMERS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF JINAN UNIVERSITY (CN) 2018-09-20 US disclosed
CN-108473434-A Substituted quinolone analog derivative or its pharmaceutically acceptable salt or stereoisomer and its Pharmaceutical composition and application 暨南大学 2018-08-31 CN disclosed
EP-3339294-A1 PHARMACEUTICAL COMPOSITION AND APPLICATION REPLACING QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER Jinan University (CN) 2018-06-27 EP disclosed
CN-106467541-A Substituted quinolone analog derivative or its pharmaceutically acceptable salt or stereoisomer and its Pharmaceutical composition and application 暨南大学 2017-03-01 CN disclosed
WO-2017028797-A1 PHARMACEUTICAL COMPOSITION AND APPLICATION REPLACING QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER 暨南大学 2017-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180265496-A1 SUBSTITUTED QUINOLONE DERIVATIVES, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR STEREOISOMERS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF NRAS, AXL, ABL1 MAPT 4122/4885KDM4E 1861/4885HPGD 1326/4885
US-10683278-B2 Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof NRAS, AXL, ABL1 MAPT 4122/4885KDM4E 1861/4885HPGD 1326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.